Research programme: recombinant human hyaluronidase-based subcutaneous biologics - Pfizer
Alternative Names: PF 06744547Latest Information Update: 16 Jul 2016
At a glance
- Originator Pfizer
- Class Recombinant proteins
- Mechanism of Action PCSK9 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (SC)
- 21 Dec 2012 Early research in Undefined indication in USA (SC)